Rituxan Granted Priority Review Status By FDA

Rituxan (rituximab) has been granted "priority" review status by the U.S. Food and Drug Administration as a treatment for rheumatoid arthritis. Priority review means that the FDA will make a decision regarding rituxan for rheumatoid arthritis within six months rather than ten months which is considered standard.

UPDATE: On 03/01/2006, Rituxan (rituximab) was FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).

• Rituxan Approved for Rheumatoid Arthritis - The Facts of Rituxan
• Subsequent Rituxan Treatment Yields Better Outcomes
• More About Rituxan (rituximab)